Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;32(3):323-336.
doi: 10.1016/j.annonc.2020.11.022. Epub 2020 Dec 9.

Immunotherapy for early breast cancer: too soon, too superficial, or just right?

Affiliations
Free article
Review

Immunotherapy for early breast cancer: too soon, too superficial, or just right?

M A Franzoi et al. Ann Oncol. 2021 Mar.
Free article

Abstract

Immunotherapy emerged as a new treatment modality for breast cancer, and its use is approved in combination with chemotherapy for first-line therapy in metastatic triple-negative breast cancer overexpressing PD-L1. As immune checkpoint inhibitors alone have modest clinical activity in advanced breast cancer, there is a growing interest in combinatorial modalities, and particularly for their rapid development in the early disease setting. The plethora of ongoing immunotherapy trials in early breast cancer comes at a time when solid data in advanced disease are still imperfect. This review offers a perspective on the efforts to establish the efficacy and safety of immunotherapeutic agents in early breast cancer.

Keywords: Immunotherapy; clinical trials; early breast cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosure ER: Investigator-initiated trial (funds paid to institution): AstraZeneca, BMS. Consultancy/advisory board: Astra Zeneca, Merck, Roche, Pierre Fabre. MP: Board member (scientific board): Oncolytics, Radius. Consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Oncolytics, Periphagen, Pfizer, Roche, Seattle Genetics. Research grants to her institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon. Speaker's bureau/stock ownership: none. MAF has declared no conflicts of interest.

Substances

LinkOut - more resources